Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Asian Journal of Biochemistry
Year: 2009  |  Volume: 4  |  Issue: 1  |  Page No.: 13 - 21

Nephrotoxicity Reduction by Fixed Dose Combination of Cephalosporins and Aminoglycosides in Mus musculus Mice

V.K. Dwivedi, M. Chaudhary, A. Soni and S.M. Shrivastava    

Abstract: Free radicals are causative factors for aminoglycoside induced renal toxicity. The aim of present study was to evaluate effect of fixed dose combination of cefepime+amikacin (Potentox) as well as ceftazidime+tobramycin (Tobracef) antibiotics on antioxidant enzymes (Super oxide dismutase, Catalase and Glutathione reductase) along with (free radical mediated damage) malonaldialdehyde levels and extracellular antioxidant enzymes (creatinine, total bilirubin and uric acid enzymes ) in kidney tissue of Mus musculus mice. Present findings showed that the activities of the antioxidant enzymes were significantly lowered along with increase in MDA (malonaldialdehyde) levels and extracellular antioxidants after single treatment of aminoglycosides (amikacin and tobramycin) as compared to control group. A significant improvement in antioxidant enzymes along with significant decrease in creatinine, total bilirubin, uric acid and malonaldialdehyde (MDA) levels were observed in fixed dose combination of cefepime plus amikacin as well as ceftazidime+tobramycin treated groups compared to amikacin and tobramycin alone treated group. These results indicate that a fixed dose combination of cephalosporins with aminoglycosides using chemical vector mediated technology acts as an antioxidant and prevents nephrotoxicity induced by aminoglycosides.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility